|
Apr 23
|
5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms
|
|
Apr 23
|
Esperion to Report First Quarter 2025 Financial Results on May 6
|
|
Apr 22
|
Esperion Therapeutics (ESPR) Loses -51.03% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
|
|
Apr 21
|
Esperion Therapeutics Inc (ESPR) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ...
|
|
Feb 18
|
Esperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4
|
|
Jan 2
|
Esperion to Participate in Upcoming 43rd Annual J.P. Morgan Healthcare Conference
|
|
Nov 26
|
Otsuka Submits New Drug Application in Japan for Bempedoic Acid in the Treatment of Hypercholesterolemia
|
|
Oct 3
|
Is Esperion Therapeutics, Inc. (ESPR) the Best NASDAQ Stock Under $5?
|
|
Oct 2
|
Esperion EU Partner Reports Final Real-World Results from MILOS German Cohort Demonstrating Strong Increase in LDL-C Goal Achievement With Addition of Bempedoic Acid
|
|
Sep 25
|
Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
|
|
Sep 5
|
Esperion to Participate in Upcoming 2024 Cantor Global Healthcare Conference
|
|
Sep 3
|
Esperion Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe)
|
|
Jul 25
|
Esperion to Report Second Quarter 2024 Financial Results on August 12
|
|
Jul 24
|
Esperion to Participate in Upcoming BTIG Biotech Conference
|
|
Jun 7
|
Why Is Catalyst (CPRX) Up 0.7% Since Last Earnings Report?
|
|
May 14
|
Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET®
|
|
May 10
|
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
|
|
May 8
|
Esperion (ESPR) Q1 Earnings Beat, Stock Up on Strong Revenues
|
|
May 8
|
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q1 2024 Earnings Call Transcript
|
|
May 8
|
Esperion Therapeutics Inc (ESPR) Q1 2024 Earnings Call Transcript Highlights: Soaring Revenues ...
|